30 closest matches · ranked by relevance
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Refractory or Recurrent Solid Tumors · Rhabdomyosarcoma · Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Primary: Phase 1: Recommended Phase 2 Dose (RP2D) of Eribulin Mesilate in Combination With Irinotecan Hydrochloride — 1.4; 40 mg/m^2
Pediatric Solid Tumor · Refractory Tumor · Recurrent Tumor
Primary: Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab — 1; 1 Participants
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
Childhood Solid Neoplasm · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: Number of Patients With Cycle 1 and 2 Dose Limiting Toxicities Attributable to Nanoparticle Albumin-bound Rapamycin — 1; 2; 1; 1 Participants
Cancer · Refractory Solid Tumor
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPIID) of Cetuximab in Combination With Irinotecan — 250; 250; 16; 20 mg/m2
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Blastic Phase · Childhood Acute Promyelocytic Leukemia With PML-RARA · Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Patients With Treatment-related Dose Limiting Toxicity in Cycle 1 by Dose Level — 0; 0; 5; 1 Participants
Recurrent and Refractory Solid Tumors
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus — 11 milligram per square meter (mg/m^2)
Recurrent Childhood Ependymoma
Primary: Objective Response Rate (Complete Response Rate and Partial Response Rate) Following Treatment With Everolimus for Children With Recurrent or Progressive Ependymomas…
Adult Solid Neoplasm · Childhood Solid Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: The Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose of Temozolomide and Talazoparib Combination Therapy — 0; 0; 1; 2…
Solid Tumor · Lymphoma · Osteosarcoma
Primary: Number of Patients With Dose-Limiting Toxicities (DLT) — 0; 2 Participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Non-Hodgkin Lymphoma · Ann Arbor Stage IV Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 0 percentage of patients
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Brain Stem Neoplasm · Pineal Region Neoplasm · Recurrent Lymphoma
Primary: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat — 4 mg/m²
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (Complete Response/Partial Response) — 0 percentage of participants
Neuroblastoma · Medulloblastoma · Relapse
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2
Malignant Glioma · Recurrent Brain Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: Number of Dose Limiting Toxicities of Selinexor — 0; 4; 1; 2 Participants
Pediatrics · Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of Eribulin Mesylate — 1.4 mg/m^2
Tumors · Solid Malignant Tumors · Osteosarcoma
Primary: Cohort 1: Recommended Dose (RD) of Lenvatinib — 14 milligram per square meter (mg/m^2)
CNS Embryonal Tumor, Not Otherwise Specified · Malignant Glioma · Recurrent Atypical Teratoid/Rhabdoid Tumor
Primary: Maximum Tolerated Dose of Ribociclib and Everolimus — 120; 1.2 mg/m^2/day
Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Rhabdomyosarcoma · Recurrent Childhood Soft Tissue Sarcoma
Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants
Neuroblastoma · Medulloblastoma · Brain Tumors
Primary: Determine Feasibility Using Days From the Date of Biopsy to Date of Start of Treatment — 12.2; 19.9; 14.9 Days
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events